SIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-M™ Autologous SIRPαlow Activated Macrophage Immunotherapy

By WebmasterMay 1, 2023November 1st, 2024No Comments

SIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-M™ Autologous SIRPαlow Activated Macrophage Immunotherapy

Previous PostVESTECK SAB Member Accepts International Leadership Appointment
Next PostTreventis Partners its Preclinical Program in Alzheimer's Disease with Takeda